Herbal medicine has been proven effective against COVID-19 as Qing Guan Yi Hao developed by the National Research Institute of Chinese Medicine helped cure 21 patients. It's also effective against the beta and delta variants.
Developed by the National Research Institute of Chinese Medicine (NRICM) in 2020, the treatment NRICM101, known in Chinese as Qing Guan Yi Hao, or RespireAid, contains 10 herbs, including indigowoad roots, fish mints, and others. The medicine has proven effective through many clinical trials to reduce the chance of severe illness in coronavirus patients and even helped cured 21 patients in 2020. An emergency permit was finally granted by the Ministry of Health and Welfare (MOHW) in May of 2021. The latest research shows that RespireAid is not only effective against the original Wuhan strain but also very effective against the beta and delta variants.
Huang Chien-jung, President of Taipei Chinese Medical Association："Honeysuckles, golden bellflowers, and indigo woad roots are all very good for clearing the heat and removing toxins in the body. They work very well to protect against viruses entering the throat."
The NRICM said that the medicine can prevent the coronavirus spike protein from binding to the cell receptor ACE2, which is the protein that provides the entry point for the coronavirus to hook into during initial infection and infect a wide range of human cells. This is like preventing the key from opening the lock. In view of new local outbreaks of COVID-19 in May, the NRICM started working on developing a new generation of RespireAid medicine which serves to help reduce the development of pulmonary fibrosis and other side effects experienced by severe COVID patients. Preliminary clinical studies show that the death rate can be reduced by 50 percent.
Chiou Wen-fei, Deputy Director, NRICM："We made improvements in the new generation of NRICM101 medicine and right now our studies show that the COVID death rate can be reduced by 50 percent."
Eight pharmaceutical companies have received emergency authorization from the MOHW to manufacture the RespireAid compound for clinical treatment in Taiwan. Pharmaceutical companies look forward to having full approval in the future. The NRICM will reveal the new formula to the new generation of RespireAid and its clinical trial results during their next conference on Oct. 22.